Granisetron oral solution - PediatRx

Drug Profile

Granisetron oral solution - PediatRx

Alternative Names: Granisol

Latest Information Update: 18 Apr 2012

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator PediatRx
  • Class Analgesics; Antiemetics; Azabicyclo compounds; Indazoles; Small molecules
  • Mechanism of Action Serotonin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Chemotherapy-induced nausea and vomiting

Most Recent Events

  • 18 Apr 2012 Granisetron oral solution - PediatRx is available for licensing as of 13 Mar 2012. http://www.apricusbio.com
  • 28 Jan 2012 Apricus Biosciences acquires granisetron oral solution from PediatRx for non-US territories and receives copromotion rights within USA
  • 14 Apr 2011 Granisetron oral solution - PediatRx is available for licensing in World (excluding USA) as of 14 Apr 2011. http://www.pediatrx.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top